A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Sitagliptin and Metformin (JANUMET)

Dipeptidyl Peptidase 4 Inhibitor class · 1 generic manufacturer · 2 ANDAs filed at FDA.

First FDA approval2007-03-30
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$5.03/unit
19 NDCs benchmarked, lowest of all strengths.
Average NADAC
$6.33
Across all dosage forms in distribution.
Highest NADAC
$10.56
Range is tight.
Plans with PA
5 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Sitagliptin and Metformin used for?

Sitagliptin and Metformin is a Dipeptidyl Peptidase 4 Inhibitor medication tracked in Medicare Part D.

Is there a generic for Sitagliptin and Metformin?

Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Sitagliptin and Metformin?

Across 329 Part D plans, Sitagliptin and Metformin averages $6.33/unit (NADAC). Lowest available: $5.03/unit. Highest in distribution: $10.56/unit.

Is Sitagliptin and Metformin on the FDA shortage list?

No. Sitagliptin and Metformin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Dipeptidyl Peptidase 4 Inhibitor4 alternatives in D1
01
Linagliptin
Brand: Tradjenta
$16.80Lowest NADAC
7Generic mfrs
$1.64BCY24 Part D spend
Compare →
02
Linagliptin and Metformin
Brand: Jentadueto
$8.44Lowest NADAC
4Generic mfrs
CY24 Part D spend
Compare →
03
Sitagliptin
Brand: JANUVIA
$10.04Lowest NADAC
3Generic mfrs
$4.88BCY24 Part D spend
Compare →
04
Sitagliptin Hydrochloride Oral
Brand: BRYNOVIN
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (19 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.